Stimulation of anti-melanoma immune effectors via modified tumour cells exhibiting inhibited IGF-I and low CD9

Biomedicine and Pharmacotherapy

Volumn 61, Issue 8, 2007, Pages 494-498

  Trabado, Séverine ^a   Van Binh, Pascale Nguyen ^b   Martin, Chantal ^c   Lafarge Frayssinet, Christiane ^d   Lone, Yu Chun ^b   Trojan, Jerzy ^b   Warnet, Jean Michel ^a   Duc, Huynh Thien ^a,b  

^a Centre Universitaire des Saints Pères   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CNRS   (France)

Author keywords

Cellular humoral immune effectors; Modified melanoma cells

Indexed keywords

CD9 ANTIGEN; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELLULAR IMMUNITY; CONTROLLED STUDY; CULTURE MEDIUM; HUMORAL IMMUNITY; IMMUNOSTIMULATION; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD; CELL LINE, TUMOR; CELL SURVIVAL; FLOW CYTOMETRY; IMMUNITY, CELLULAR; INSULIN-LIKE GROWTH FACTOR I; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; VACCINATION;

EID: 34548535342     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.07.004     Document Type: Article

References (25)

1. Froesch E.R., Schmid C., Schwander J., and Zapf J. Actions of insulin-like growth factors. Annu Rev Physiol 47 (1985) 443-467
2. Humbel R.E. Insulin-like growth factors I and II. Eur J Biochem 190 (1990) 445-462
3. Sell C., Baserga R., and Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 55 (1995) 303-306
4. Macaulay V.M. Insulin-like growth factors and cancer. Br J Cancer 65 (1992) 311-320
5. LeRoith D., Baserga R., Helman L., and Roberts Jr. C.T. Insulin-like growth factors and cancer. Ann Intern Med 122 (1995) 54-59
6. Rho O., Bol D.K., You J., Beltran L., Rupp T., and DiGiovanni J. Altered expression of insulin-like growth factor I and its receptor during multistage carcinogenesis in mouse skin. Mol Carcinog 17 (1996) 62-69
7. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 (1998) 563-566
8. Lee A.V., Hilsenbeck S.G., and Yee D. IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat 47 (1998) 295-302
9. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 4 (2004) 505-518
10. Trojan J., Blossey B.K., Johnson T.R., Rudin S.D., Tykocinski M., Ilan J., et al. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci USA 89 (1992) 4874-4878
11. Resnicoff M., Sell C., Rubini M., Coppola D., Ambrose D., Baserga R., et al. Rat glioma cells expressing an antisense RNA to the insulin-like growth factor-I (IGF-I) receptor are non tumorigenic and induce regression of wild-type tumours. Cancer Res 54 (1994) 2218-2222
12. Trojan J., Duc H.T., Upegui-Gonzales L.C., Hor F., Guo Y., Anthony D., et al. Presence of MHC-I and B-7 molecules in rat and human glioma cells expressing antisense IGF-I mRNA. Neurosci Lett 212 (1996) 9-12
13. Lafarge-Frayssinet C., Duc H.T., Frayssinet C., Sarasin A., Anthony D., Guo Y., et al. Antisense insulin-like growth factor I transferred into a rat hepatoma cell line inhibits tumorigenesis by modulating major histocompatibility complex I complex cell surface expression. Cancer Gene Ther 4 (1997) 276-285
14. Fidler I.J. Biological behaviour of malignant melanoma cells correlated to their survival in vivo. Cancer Res 35 (1975) 218-224
15. Trabado S., Nguyen Van Binh P., Martin C., Lafarge-Frayssinet C., Thevenin M., Baudouin F., et al. Modulated expression of cell surface molecules and in vivo outgrowth of modified melanoma cells. Biomed Pharmacother 60 (2006) 693-697
16. Lafarge-Frayssinet C., Martin C., Nguyen Van Binh P., Achard-Ellouk S., Duc H.T., Frayssinet C., et al. Adenovirus-mediated anti insulin-like growth factor I gene transfer for the treatment of hepatocellular carcinoma. Anticancer Res 22 (2002) 3895-3904
17. Moore M.W., Carbone F.R., and Bevan M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54 (1988) 777-785
18. Falo Jr. L.D., Kovacsovics-Bankowski M., Thompson K., and Rock K.L. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med 1 (1995) 649-653
19. Tanaka K., Gorelik E., Watanabe M., Hozumi N., and Jay G. Rejection of B16 melanoma induced by expression of transfected major histocompatibility complex class I gene. Mol Cell Biol 8 (1988) 1857-1861
20. Chen L., Ashe S., Brady W.A., Hellström I., Hellström K.E., Ledbetter J.A., et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71 (1992) 1093-1102
21. Townsend S.E., and Allison J.P. Tumor rejection after direct costimulation of CD8+T cells by B7-transfected melanoma cells. Science 259 (1993) 368-370
22. Hotta H., Ross A.H., Huebner K., Isobe M., Wendeborn S., Chao M.V., et al. Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res 48 (1988) 2955-2962
23. Maecker H.T., Todd S.C., and Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J 11 (1997) 428-442
24. Boucheix C., Benoit P., Frachet P., Billard M., Worthington R.E., Gagnon J., et al. Molecular cloning of the CD9 antigen. A new family of cell surface proteins. J Biol Chem 266 (1991) 117-122
25. Rubinstein E., Ziyyat A., Wolf J.P., Le Naour F., and Boucheix C. The molecular players of sperm-egg fusion in mammals. Semin Cell Dev Biol 17 (2006) 254-263